ARTICLE | Clinical News
Zelboraf vemurafenib regulatory update
June 17, 2013 7:00 AM UTC
Roche and Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) said they reached an agreement on the price for melanoma drug Zelboraf vemurafenib. The parties, who declined to disclose the negotiated price, said in a joint statement the negotiations were "not easy, but constructive and fair." The agreement comes after GKV-Spitzenverband said in late May that the price for Zelboraf had been determined through independent arbitration after the parties failed to agree on a price. ...